Article ; Online: Treatment of paradoxical eczematous eruption in psoriasis treated with secukinumab: A case report.
2023 Volume 102, Issue 6, Page(s) e32844
Abstract: Rationale: Eczematous eruption is an increasingly recognized form of drug-related eruption, typically reported in association with interleukin 17 (IL-17)A inhibitors. However, severe paradoxical eczematous eruption due to IL-17A inhibitors has been ... ...
Abstract | Rationale: Eczematous eruption is an increasingly recognized form of drug-related eruption, typically reported in association with interleukin 17 (IL-17)A inhibitors. However, severe paradoxical eczematous eruption due to IL-17A inhibitors has been rarely reported. Herein, we reported a case of a man with severe psoriasis with erythematous scaly plaques on the scalp, trunk, and arms and legs after the administration of secukinumab was initiated. Patient concerns: We reported a case of a 20-year-old man with severe psoriasis with erythematous scaly plaques on the scalp, trunk, and arms and legs after the administration of secukinumab was initiated. A skin biopsy was performed. It revealed spongiotic dermatitis consistent with eczematous reaction. Direct and indirect immunofluorescence assays were negative. Diagnoses: He was diagnosed with eczematous eruption. Interventions: Discontinuation of secukinumab and administration of cyclosporine and prednisone were considered. Outcomes: Significant improvement was observed, with no adverse events. Conclusion: Our case shows that eczematous eruption can paradoxically occur in patients on IL-17A inhibitors and this report is expected to increase awareness of the rising number of cutaneous eruptions related to biological agents. |
---|---|
MeSH term(s) | Humans ; Male ; Young Adult ; Antibodies, Monoclonal, Humanized/adverse effects ; Drug Eruptions/etiology ; Eczema/chemically induced ; Eczema/complications ; Erythema ; Exanthema/chemically induced ; Interleukin-17 ; Psoriasis/drug therapy ; Psoriasis/complications |
Chemical Substances | Antibodies, Monoclonal, Humanized ; Interleukin-17 ; secukinumab (DLG4EML025) |
Language | English |
Publishing date | 2023-01-05 |
Publishing country | United States |
Document type | Case Reports ; Journal Article |
ZDB-ID | 80184-7 |
ISSN | 1536-5964 ; 0025-7974 |
ISSN (online) | 1536-5964 |
ISSN | 0025-7974 |
DOI | 10.1097/MD.0000000000032844 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Ua VI Zs.171: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.